Peptide Regulation of Chondrogenic Stem Cell Differentiation
Review of earlier studies · 2023
- What was studied
- Review of stem-cell differentiation and cartilage research
- Main finding
- Describes the cartilage polypeptide complex PCC and its AED component. The authors reported a Russian Phase II osteoarthritis program in 2023. They connect MSC and fibroblast findings to a cartilage-repair hypothesis.
Study data at a glance
- Participants or experimental model
- Review of stem-cell differentiation and cartilage research
- Reported results
- Describes the cartilage polypeptide complex PCC and its AED component. The authors reported a Russian Phase II osteoarthritis program in 2023. They connect MSC and fibroblast findings to a cartilage-repair hypothesis.
Study limitations and source details
Study limitations
- The reported trial concerns PCC, not a trial of isolated Cartalax.
- Trial identifier, protocol, enrollment and published human outcomes have not been recovered. Phase II is an attributed 2023 statement, not verified current status.
Source details
Full-text XML checked, including PCC/AED discussion and references 7, 9, 68–70. Trial documents were not supplied by this review.
Sources checked
Citation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G. Peptide Regulation of Chondrogenic Stem Cell Differentiation Int J Mol Sci 24(9):8415. PMID 37176122
Study source ↗ · DOI 10.3390/ijms24098415 · Bibliography entry · Link to this summary
Related compounds
Cartalax
A synthetic tripeptide, Ala–Glu–Asp (AED, also called T-31), studied in cartilage, bone and joint research. Some related experiments used a cartilage extract containing AED.
PCC
A polypeptide mixture extracted from animal cartilage. The preparation contains the tripeptide Ala–Glu–Asp (AED), which has also been studied separately as synthetic Cartalax.